June 1, 2020 by admin 0 Comments

All About Extracellular Marix, And its application

ROKIT Open Innovation
All About Extracellular Marix, And its application
- 2020. 06. 12. FRI. 11:00 AM -

"Welcome to ROKIT & Calia Webinar"

This webinar will explain what is Extracellular Matrix,
what are the research areas ECM is applied,
and what are the limitations of current ECM products and the solution to it.

* This webinar is hosted by ROKIT Healthcare INC and CALIA

Check out the webinars for more details.

Joshua Jaeyun Kim, PhD

  • HumaTein/Bioink SBU President

Career Highlight

  • Ph.D., Dept of Biomedical Engineering, Boston University
  • Postdoctoral Research Associate, Boston University
Live Platform
All About Extracellular Marix, And its application
2020.06.12. FRI 11:00 AM
Please RSVP today, we will send you ZOOM link soon!

Privacy Policy

Collection of Information : Name, Email, Institution, Dept Name Purpose of Collection : Contact Period of Use : In principle, after the purpose of collecting and using personal information is achieved, such information shall be destroyed without delay. However, personal information may be kept for a certain period as specified in the relevant statutes, if it is necessary to preserve it according to the provisions of the relevant statutes, as follows. - Records on consumer complaints or dispute handling : 3 years (Law on Consumer Protection in Electronic Commerce, etc.) - Agree to collect and use of personal information above. (you can inquire after consent)

ROKIT HEALTHCARE is a 4D Bioprinting and Biotechnology company based in South Korea and is committed to bettering humanity through our contributions to the field of regenerative medicine.

April 23, 2020 by admin 0 Comments

3D Bioprinted Vascularized Tumour for Drug Testing

Seokgyu Han 1, Sein Kim 2, Zhenzhong Chen 1, Hwa Kyoung Shin 3,4,5, Seo-Yeon Lee 6, Hyo Eun Moon 7,8, Sun Ha Paek 7,8 and Sungsu Park 1,2,9,10,*
An in vitro screening system for anti-cancer drugs cannot exactly reflect the efficacy of drugs in vivo, without mimicking the tumour microenvironment (TME), which comprises cancer cells interacting with blood vessels and fibroblasts. Additionally, the tumour size should be controlled to obtain reliable and quantitative drug responses. Herein, we report a bioprinting method for recapitulating the TME with a controllable spheroid size. The TME was constructed by printing a blood vessel layer consisting of fibroblasts and endothelial cells in gelatine, alginate, and fibrinogen, followed by seeding multicellular tumour spheroids (MCTSs) of glioblastoma cells (U87 MG) onto the blood vessel layer. Under MCTSs, sprouts of blood vessels were generated and surrounding MCTSs thereby increasing the spheroid size. The combined treatment involving the anti-cancer drug temozolomide (TMZ) and the angiogenic inhibitor sunitinib was more effective than TMZ alone for MCTSs surrounded by blood vessels, which indicates the feasibility of the TME for in vitro testing of drug efficacy. These results suggest that the bioprinted vascularized tumour is highly useful for understanding tumour biology, as well as for in vitro drug testing.